Cures Acceleration Network Review Board Real-World Applications for Mature Programs (RAMP) Working Group

Charge

In 2019, NCATS established a Cures Acceleration Network Review Board (CAN RB) working group to assess how NCATS can accelerate translational science implementation and foster the uptake of mature CAN RB-supported tools and technologies into real-world use and practice.

The CAN RB Real-World Applications for Mature Programs (RAMP) working group is charged with making recommendations to the CAN RB and the NCATS director on topics that include, but are not limited to, the following:

  • Assessment of CAN authorities: Identify ways to better leverage the authorities to ensure that NCATS is using its full power for advancing and accelerating translational science into implementation.
  • Project prioritization and sunsetting: Provide input on factors that NCATS should consider in assessing the turnover of CAN projects, which should include considerations for introducing and prioritizing new projects and for graduating or transitioning existing CAN projects.
  • Long-term sustainability: Identify factors that facilitate the transition, adoption and adaptation of CAN-funded projects or initiatives into real-world settings.
  • Stakeholder engagement: Identify factors to enhance stakeholder engagement and lower barriers to advancing translational research across the many sectors.
  • Other ideas as determined by the working group

The CAN RB RAMP working group is currently in progress and is expected to deliver formal recommendations to the CAN RB in spring 2021.

Related Reports

“Maximizing the Goals of the Cures Acceleration Network to Accelerate the Development of New Drugs and Diagnostics: A Workshop” took place June 4–5, 2012. Review the workshop summary (PDF - 601KB) or visit the National Academy of Medicine (formerly the Institute of Medicine) website for more information about this event.

Roster

CO-CHAIRS

  • Chairperson
    Ronald J. Bartek, M.A. 
    Co-Founder and Founding President
    Friedreich’s Ataxia Research Alliance
    Arlington, Virginia

MEMBERS

  • Margaret Anderson
    Managing Director
    Deloitte Consulting, LLP
    Rosslyn, Virginia
  • Christopher Flores, Ph.D.
    Vice President, Glutamatergic Pathway Area Leader
    Janssen
    Spring House, Pennsylvania
  • Christopher Gibson, Ph.D.
    Co-Founder and CEO
    Recursion Pharmaceuticals
    Salt Lake City, Utah
  • Kathy Hudson, Ph.D.
    Founder and Consultant
    Hudson Works, LLC
    Washington, D.C.
  • Geoffrey Ling, M.D., Ph.D.
    Professor of Neurology
    Johns Hopkins University
    Baltimore, Maryland
  • Megan O’Boyle
    Principal Investigator
    Phelan-McDermid Syndrome Data Network
    Arlington, Virginia
  • Alan Palkowitz, Ph.D.
    Senior Research Professor of Medicine
    University School of Medicine
    Indianapolis, Indiana
  • Mary Perry, Ph.D.
    Program Leader
    Office of Strategic Coordination
    Division of Program Coordination, Planning, and Strategic Initiatives
    Office of the Director
    National Institutes of Health
    Bethesda, Maryland
  • Elizabeth Stoner, M.D.
    Executive Partner
    MPM Capital
    New York, New York
  • Laura Lyman Rodriguez, Ph.D.
    Interim Chief Program Support Officer, Senior Advisor to the Executive Director
    Patient-Centered Outcomes Research Institute
    Washington, D.C.
  • David Wholley, M.Phil.
    Senior Vice President, Research Partnerships
    Foundation for the National Institutes of Health
    Bethesda, Maryland

EX OFFICIO

  • Anna Ramsey-Ewing, Ph.D.
    Director
    Office of Grants Management and Scientific Review
    National Center for Advancing Translational Sciences
    National Institutes of Health
    Bethesda, Maryland

EXECUTIVE SECRETARY

  • Samantha G. Jonson, M.P.S.
    Dissemination and Implementation Strategy Lead
    Office of the Director
    National Center for Advancing Translational Sciences
    National Institutes of Health
    Bethesda, Maryland